media – Page 284 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia

German group Merck has announced two new drug discovery collaborations with BenevolentAI and Exscientia to harness artificial intelligence (AI)-driven design and discovery capabilities to accelerate drug discovery. The partnerships are expected to generate several new clinical development drug candidates in key therapeutic areas of oncology, neurology and immunology. Under the terms of the agreements, three potential targets have been selected to initiate each partnership, with the potential of identifying and nominating additional targets in the future. The collaborations will focus on advancing small-molecule development candidates, which Merck will select for further preclinical and clinical development. As part of the agreements, both UK-based companies will receive upfront payments from Merck and will be eligible for future milestone payments plus tiered royalties based on net sales. Exscientia will receive an upfront payment of $20m and up to $674m in milestone payments if all three projects meet their objectives. Meanwhile, BenevolentAI is set ...
- Source: drugdu
- 106
- October 1, 2023
MIT study reveals why certain immunotherapies do not always work

A new Massachusetts Institute of Technology (MIT) study has revealed a potential explanation as to why certain immunotherapies for cancerous tumours do not always work as predicted. If validated in clinical trials, the findings could help doctors identify cancer patients who would benefit the most from drugs known as checkpoint blockade inhibitors. Checkpoint blockade inhibitors work by stimulating immune cells to destroy tumours in the body’s T cell response. In previous studies, findings have shown that these drugs work effectively in patients whose tumours have a large number of mutated proteins. However, 50% of patients who received the US Food and Drug Administration-approved checkpoint blockade inhibitor, pembrolizumab, did not respond well or only showed short-lived responses, despite their tumours showing high mutational burden. In a study of mice, the researchers revealed that measuring the diversity of mutations within a tumour generated a more accurate prediction as to whether immunotherapy treatment ...
- Source: drugdu
- 109
- October 1, 2023
Kezar and Everest enter lupus nephritis therapy development deal

Kezar Life Sciences and Everest Medicines have signed a partnership and licence agreement for the development and commercialisation of zetomipzomib for lupus nephritis (LN) in select territories. The territories covered under the agreement include Greater China, South Korea and South East Asia. As per the deal terms, Kezar is eligible to receive up to $132.5m in initial upfront and milestone payments contingent on meeting development, regulatory and commercialisation goals in the future. Kezar will also receive tiered royalty payments on net product sales from Everest. Everest will obtain sole rights for developing and marketing zetomipzomib in regions such as Greater China, Indonesia, Malaysia, the Philippines, Singapore, South Korea, Thailand and Vietnam. Everest will also collaborate with Kezar for the Phase IIb PALIZADE clinical trial of zetomipzomib, an immunoproteasome inhibitor of Kezar, in active LN patients in Greater China, South Korea and South East Asia. In the licensed territories, Everest will ...
- Source: drugdu
- 157
- October 1, 2023
Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years

U.S. health care providers wrote more than nine million prescriptions for Ozempic, Wegovy and similar diabetes and obesity drugs during the last three months of 2022, according to a new analysis released Wednesday. The report, from analytics firm Trilliant Health, shows that quarterly prescriptions for those drugs increased 300% between early 2020 and the end of last year. Novo Nordisk ’s weekly diabetes injection Ozempic accounted for more than 65% of total prescriptions as of the end of 2022, and was primarily prescribed off-label for its ability to help patients lose weight. The data further confirms the rise in demand for that group of drugs, which have fueled a frenzy among Americans and on Wall Street for their ability to cause significant weight loss. Those treatments, known as GLP-1s, mimic a hormone in the gut to suppress a person’s appetite. But the rate of future prescription volumes will largely depend ...
- Source: drugdu
- 111
- September 30, 2023
Portsmouth NHS Trust maternity team enhances patient experience

Portsmouth NHS Trusthas significantly improved patient experiences by automating appointments, referrals and record management processes. In a first-of-its-kind deployment, Portsmouth Hospitals University NHS Trust’s Maternity Services & Midwifery unit has worked with intelligent automation companies, Digital Workforce and PSTG, to boost patient experiences. Since the project began, patient waiting times to receive an appointment have reduced from 6-8 weeks to just 24 hours, while appointment capacity has increased by a third. Furthermore, the deployment has saved 18,000 hours of staff time, the equivalent of £225,000 in internal staffing costs or 12 full-time employees. Significantly, the Trust has cut a considerable backlog which, at its height, saw 5,000 patients waiting for appointments. The Trust incorporated Digital Workforce’s Intelligent Automation technology by feeding it with the processes of an end-to-end patient journey, along with the required safety standards. After testing, the solution was deployed to run constantly, capturing and sharing data across ...
- Source: drugdu
- 115
- September 30, 2023
Cancer Research UK partners with French cancer institute

Cancer Research UK has announced its international partnership with France’s Institut National Du Cancer (INCa), investing £8.6m to drive world-class global cancer research. As part of the global Cancer Grand Challenges initiative, the partnership will help fund world-class researchers to take on cancer’s toughest challenges. Claiming almost ten million lives every year, cancer is the second leading cause of death worldwide. The INCa is currently the first to pledge funds to support several teams in a single round of the Cancer Grand Challenges initiative, as well as the initiative’s original founding partners, Cancer Research UK and the US National Cancer Institute (NCI). Since its founding in 2020, more than £210m has been invested in the initiative, which aims to build a scientifically elite, interdisciplinary community to fill knowledge gaps in cancer and drive progress. The initiative comprises diverse international organisations, collaborators and research leaders, including the Scientific Foundation of the ...
- Source: drugdu
- 97
- September 30, 2023
Genentech, PeptiDream Ink Potential $1B Radiopharma Deal

By Kate Goodwin Pictured: Businessmen shaking hands/iStock, Tippapatt Japanese biopharma PeptiDream on Wednesday announced yet another licensing agreement with Roche’s Genentech, this time worth up to $1 billion. The latest deal builds on previous partnerships between the two companies starting in December 2015 with licensing in 2016 and an expansion deal in 2018. PeptiDream will receive $40 million upfront for R&D of its macrocyclic peptide-radioisotope drug conjugates. Going forward, another $1 billion is on the line in milestones plus tiered royalties of product sales to markets outside of Japan. PeptiDream will oversee preclinical activities to develop a peptide-RI drug conjugate and retain rights in Japan for any products developed. While a particular target was not disclosed, PeptiDream CEO Patrick Reid said in a statement that the company hopes to “bring innovative first-in-class peptide radiopharmaceuticals to patients worldwide.” The peptide-RI drug conjugates in the deal with Genentech are designed to use ...
- Source: drugdu
- 120
- September 30, 2023
Medicaid/CHIP Coverage To Be Reinstated for 500K People

Thirty states have been conducting Medicaid and CHIP automatic renewals incorrectly, leading to many individuals being wrongly removed from coverage. Because of this, nearly 500,000 children and other individuals will have their coverage reinstated. By MARISSA PLESCIA After determining an issue in the way many states were handling Medicaid and CHIP redeterminations, the U.S. Department of Health and Human Services (HHS) announced Thursday that coverage will be reinstated for nearly 500,000 children and other individuals.“Thanks to swift action by HHS, nearly half a million individuals, including children, will have their coverage reinstated, and many more will be protected going forward. HHS is committed to making sure people have access to affordable, quality health insurance – whether that’s through Medicare, Medicaid, the Marketplace, or their employer,” said HHS Secretary Xavier Becerra in a statement. “We will continue to work with states for as long as needed to help prevent anyone eligible ...
- Source: drugdu
- 190
- September 30, 2023
Meitheal partners with Chinese company for US licencing of insulin biosimilars

Meitheal Pharmaceuticals has signed an exclusive licensing agreement with the China-based Tonghua Dongbao Pharmaceutical to commercialise three insulin biosimilars in the US. The insulin biosimilars include two rapid-acting insulins, namely insulin lispro and insulin aspart, and the long-acting insulin glargine. The rights were acquired by Meitheal’s parent company Nanjing King-Friend Biochemical Pharmaceutical. Eli Lilly reported global sales of $440.4m for the branded version of insulin lispro Humalog in n Q2 2023, while Sanofi’s Lantus (insulin glargine) had global sales of $353m in the same period, as per the company’s Q2 financials. Meitheal will have exclusive US marketing rights after the insulin biosimilars are approved by the US Food and Drug Administration (FDA), which is expected in 2026. As part of the agreement, both Tonghua Dongbao and Nanjing King-Friend Biochemical would be responsible for the development and supply of all three insulin biosimilars. All three companies will also share the royalties ...
- Source: drugdu
- 98
- September 30, 2023
Evaxion partners with Afrigen Biologics to develop mRNA gonorrhea vaccine

The Danish artificial intelligence (AI) biotech Evaxion has announced plans to develop an mRNA vaccine against gonorrhea in partnership with Afrigen Biologics. Gonorrhea antigens identified through Evaxion’s EDEN platform have shown strong protective effects in preclinical trials, as per the company. The partnership will investigate the function of these antigens when presented in the mRNA form. After the validation phase, the partners will discuss an agreement for clinical development and commercialisation, with the opportunity to involve additional collaborators. Cape Town, South Africa-based Afrigen Biologics is set up as a specialised centre to support mRNA vaccine development and technology transfer, will take charge of developing the mRNA vaccine in low and middle-income countries and African territories. Gonorrhea is a sexually transmitted infection, caused by the bacteria Neisseria gonorrhoeae. It heightens the vulnerability to HIV, a prevalent health concern in many low and middle-income countries (LMICs). Birgitte Rønø, Evaxion’s Chief Scientific Officer ...
- Source: drugdu
- 104
- September 30, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.